Kineta, Inc. Total Liabilities
Kineta, Inc. total liabilities. Based on the latest financial reports, Kineta, Inc. (KANT) has total liabilities worth $9.38 Million USD as of June 2024. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See working capital to net assets of Kineta, Inc. to evaluate short-term liquidity relative to the company's equity base.
Total Liabilities of Kineta, Inc. (2020–2023)
Total liabilities of Kineta, Inc. from 2020 to 2023. This chart illustrates how Kineta, Inc.'s total liabilities have evolved over time, based on quarterly financial data. See KANT cash flow after capex ratio to measure how efficiently the company converts operating cash flow to free cash.
Kineta, Inc. Competitors by Total Liabilities
The table below lists competitors of Kineta, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
THALASSA HLDG.NEW DL-01
F:TH2P
|
Germany | €480.38K |
|
RH Bophelo Ltd
JSE:RHB
|
South Africa | ZAC161.81 Million |
|
Tourn International AB
ST:TOURN
|
Sweden | Skr20.46 Million |
|
Fluicell AB
ST:FLUI
|
Sweden | Skr6.56 Million |
|
Golden Tobacco Limited
NSE:GOLDENTOBC
|
India | Rs2.05 Billion |
|
Wah Fu Education Group Ltd
NASDAQ:WAFU
|
USA | $3.16 Million |
|
West Cobar Metals Ltd
AU:WC1
|
Australia | AU$300.23K |
|
Priti International Limited
NSE:PRITI
|
India | Rs73.90 Million |
Liability Composition Analysis (2020–2023)
This chart breaks down Kineta, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Kineta, Inc. total assets.
Liquidity & Leverage Metrics
Kineta, Inc. Total Liabilities Ratios Explained
Kineta, Inc. total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.14 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -1.15 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 6.70 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Kineta, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Kineta, Inc. (2020–2023)
The table below shows the annual total liabilities of Kineta, Inc. from 2020 to 2023.
| Year | Total Liabilities | Change |
|---|---|---|
| 2023-12-31 | $7.22 Million | -43.86% |
| 2022-12-31 | $12.87 Million | -49.15% |
| 2021-12-31 | $25.30 Million | -29.42% |
| 2020-12-31 | $35.85 Million | -- |
About Kineta, Inc.
Kineta, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies that transform patients' lives in the United States. The company's immuno-oncology pipeline includes KVA12123, a VISTA blocking immunotherapy in development as a twice weekly monoclonal antibody (mAb) infusion drug. KVA12123 is being evaluated in a Phase 1/2 clinical trial as a monotherapy and in combinati… Read more